Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer
Kogawa, Takahiro, Yonemori, Kan, Naito, Yoichi, Noguchi, Emi, Shimizu, Chikako, Tamura, Kenji, Hosono, Ako, Matsubara, Nobuaki, Sugihara, Masahiro, Ogawa, Hayao, Majima, Shuji, Yu, Channing, Ueno, Suguru, Takano, Toshimi
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Abstract 3092: U3-1402a, a novel HER3-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent antitumor efficacy
Ueno, Suguru, Hirotani, Kenji, Abraham, Reimar, Blum, Sabine, Frankenberger, Birgit, Redondo-Muller, Mauricio, Bange, Johannes, Ogitani, Yusuke, Zembutsu, Akiko, Morita, Koji, Nakada, Takashi, Majima, Shuji, Abe, Yuki, Agatsuma, Toshinori
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article